{"id":"NCT00536731","sponsor":"AstraZeneca","briefTitle":"Symbicort Rapihaler Therapeutic Equivalence Study","officialTitle":"A 6-week, Phase III, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy and Safety of 2 Actuations Symbicort®pMDI® 40/2.25 μg Twice Daily Compared With 1 Inhalation Symbicort Turbuhaler® 80/4.5 μg Twice Daily and 1 Inhalation Pulmicort®Turbuhaler® 100 μg Twice Daily","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2007-09-28","resultsPosted":"2012-08-15","lastUpdate":"2012-08-15"},"enrollment":742,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bronchial Asthma"],"interventions":[{"type":"DRUG","name":"Symbicort Turbuhaler","otherNames":[]},{"type":"DRUG","name":"Symbicort pMDI","otherNames":[]},{"type":"DRUG","name":"Pulmicort Turbuhaler","otherNames":[]}],"arms":[{"label":"Symbicort pMDI","type":"ACTIVE_COMPARATOR"},{"label":"Symbicort Turbuhaler","type":"ACTIVE_COMPARATOR"},{"label":"Pulmicort Turbuhaler","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the this study is to evaluate the efficacy and safety of 2 actuations Symbicort®pMDI® 40/2.25 μg twice daily compared with1 inhalation Symbicort Turbuhaler® 80/4.5 μg twice daily and 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily for 6 weeks.","primaryOutcome":{"measure":"Morning Peak Expiratory Flow (PEF)","timeFrame":"Baseline to 6 weeks","effectByArm":[{"arm":"Symbicort pMDI","deltaMin":12.88,"sd":24.6},{"arm":"Symbicort Turbuhaler","deltaMin":13.78,"sd":29.7},{"arm":"Pulmicort Turbuhaler","deltaMin":4.59,"sd":27.9}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":48,"countries":["Bulgaria","Czechia","Hungary","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":253},"commonTop":[]}}